Full-Time

Staff Software Engineer/Bioinformatician

Posted on 8/8/2024

GeneDx

GeneDx

501-1,000 employees

Provides genetic testing for rare diseases

Compensation Overview

$183.7k - $229.6k/yr

Senior

Remote in USA

Category
Bioinformatics
Biology & Biotech
Software QA & Testing
Software Engineering
Required Skills
Kubernetes
Python
Docker
AWS
Requirements
  • Proficiency in Python; comfortable with working in other similar languages.
  • Experience building/consuming API calls/responses and ETL functions.
  • Experience with AWS services, Docker, Kubernetes, Helm, CI/CD, automated testing, and data logging suites/toolsets.
  • Good understanding of general software engineering patterns, best practices, and methods.
  • 8+ years professional experience (industry setting) designing and supporting robust applications using modern object-oriented frameworks.
  • Able to define and execute work across platforms over multiple quarters, as a technical project lead and contributor.
  • Have developed novel bioinformatics algorithms and products.
  • Track record of influential publications or leadership of scientific collaborations.
  • Successful history of delivering scalable production software.
  • Excellent communication skills; ability to work collaboratively with other development teams.
  • Knowledge of bioinformatics pipeline scalability, observability, and cost efficiency.
  • Be able to lead, coordinate, and execute validation efforts for new products.
  • Deep understanding of technical implementation of complex variant calling - structural variants beyond copy number.
  • Ability to improve existing variant calling algorithms.
  • Technical knowledge of NGS and non-NGS laboratory assays.
  • Prior experience working in a CAP/CLIA regulated setting.
  • Prior experience preparing for a CAP/CLIA inspection.
  • Understanding of assay panel design considerations.
  • Able to coordinate and execute efforts for modifications to existing bioinformatics products.
  • Experience troubleshooting wet-lab and dry-lab issues.
  • Strong understanding of bayesian statistics and ML in relation to common bioinformatics applications.
  • Familiarity with samtools, gatk, picard, vcftools, bedtools.
  • Familiarity with bioinformatics workflow management tools and concepts.
  • PhD strongly preferred.
Responsibilities
  • Design, write, and maintain high quality and robust software applications and services to meet team goals.
  • Design novel algorithms in support of new product offerings, lead analytical validation efforts in support of existing pipeline improvements.
  • Collaborate with teammates and product managers in developing development roadmaps and sprint planning.
  • Lead establishment and adherence to robust and compliant software development best practices.
  • Participate in software quality testing and validation.
  • Participate in cross-functional development with other teams.
  • Contribute to continuous improvement in the operating model of the team.
  • Level up your teammates to bring deeper understanding of technical know-how across teams.
  • Ensure quality technical implementation within our platform.
  • Your code is peer-reviewed through the pull request process. You lead reviews of others’ work.
  • Produce high quality code that meets company coding standards and is clearly written and documented so that other software developers can work with it.

GeneDx focuses on clinical genomics and rare disease diagnostics through genetic testing, analyzing patients' DNA to identify mutations linked to health conditions. They have sequenced over 300,000 clinical patient exomes, using samples from cheek swabs and blood to detect genetic variations, with results reported back to healthcare providers. GeneDx stands out by offering rapid testing services that deliver results in as little as seven days, which is crucial for timely diagnoses. Their goal is to lead in clinical genomics by providing fast and reliable genetic testing services that support personalized medicine.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Fabric Genomics enhances AI-powered genomic interpretation capabilities.
  • Integration with Epic Aura streamlines test ordering and reduces diagnostic errors.
  • GeneDx Discover platform accelerates drug development with vast genetic datasets.

What critics are saying

  • Integration challenges with Fabric Genomics may disrupt operations and delay synergies.
  • Increased competition from companies like Invitae could erode market share.
  • Reliance on AI raises data privacy concerns and potential regulatory scrutiny.

What makes GeneDx unique

  • GeneDx excels in rapid exome and genome testing with quick turnaround times.
  • Centrellis platform synthesizes clinical and genomic data for actionable health insights.
  • Multiscore AI tool enhances diagnostic efficiency by prioritizing genes based on clinical data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Employee Discounts

Voluntary benefits

Company News

360Dx
Apr 16th, 2025
GeneDx to Acquire Fabric Genomics in Deal Potentially Worth $51M

NEW YORK - GeneDx said Wednesday that it plans to acquire Fabric Genomics for $33 million in cash with the potential consideration rising to $51 million if certain milestones are met.

Hit Consultant
Apr 16th, 2025
Genedx Acquires Fabric Genomics For $33M, Expanding Access To Ai-Powered Genomic Interpretation

What You Should Know:– GeneDx, a company focused on improving health outcomes through genomic insights, has announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation.– The acquisition aims to position GeneDx at the forefront of the next phase of genomic medicine, characterized by decentralized testing with centralized intelligence. Following the closing of the acquisition, Fabric Genomics will initially operate independently while benefiting from GeneDx’s commercial support to accelerate its expansion.AI-Powered Genomic InterpretationThe acquisition is motivated by the increasing accessibility of DNA sequencing, which allows for the decoupling of interpretation services from physical laboratories. This decoupling is expected to provide greater flexibility in integrating genomic information into the workflows of healthcare providers and health systems, both in the U.S. and globally. Fabric Genomics’ platform is known for its ability to scale complex interpretation services and has been used to interpret challenging genetic disease cases for various large health systems, academic centers, and research partners.Through this acquisition, health systems will gain the option to use GeneDx’s centralized lab or conduct sequencing at their own facilities while leveraging GeneDx’s data and Fabric Genomics’ AI-powered interpretation platform. The companies believe that this model will lead to faster and earlier diagnoses of genetic diseases, improved patient outcomes, and reduced costs for healthcare systems.Expanding Market ReachThe acquisition will also enable GeneDx to expand its market reach into several key areas:NICU Genomic Testing: The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants.The companies aim to increase the use of rapid whole genome sequencing in NICUs, where it has the potential to reduce diagnostic time and costs and improve outcomes for infants

Stock Titan
Mar 18th, 2025
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today they have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025, and recognized as the No. 2 in the Biotech category.

The Chemical Data Company
Mar 13th, 2025
GeneDx to Present Key Research at 2025 ACMG Annual Meeting

GeneDx Showcases Groundbreaking Genomic Research at 2025 ACMG Annual Clinical Genetics Meeting

Stock Titan
Mar 13th, 2025
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights.

INACTIVE